Cipla strengthens on getting approval to sell Truvada drug in India from DCGI

24 May 2016 Evaluate

Cipla is currently trading at Rs 503.45, up by 6.05 points or 1.22% from its previous closing of Rs 497.40 on the BSE.

The scrip opened at Rs. 500.85 and has touched a high and low of Rs. 504.95 and Rs. 498.60 respectively. So far 47015 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 748.00 on 17-Aug-2015 and a 52 week low of Rs. 495.05 on 23-May-2016.

Last one week high and low of the scrip stood at Rs. 528.90 and Rs. 495.05 respectively. The current market cap of the company is Rs. 40518.32 crore.

The promoters holding in the company stood at 36.78% while Institutions and Non-Institutions held 34.17% and 27.13% respectively.

Cipla has received regulatory approval in India from the Drug Controller General of India (DCGI) to sell its version of Truvada as a preventive that can be given to healthy people to reduce their risk of getting HIV. Truvada is priced at Rs 2,200 for a month. The Truvada has been in use in India for about eight years now, but only for the treatment of people with the HIV infection. The big difference now is that it is used to prevent infection in healthy people.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Its portfolio includes 1500 plus products across therapeutic categories with one quality standard globally.

Cipla Share Price

1380.05 -17.90 (-1.28%)
19-Jan-2026 11:11 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1666.70
Dr. Reddys Lab 1168.55
Cipla 1380.05
Zydus Lifesciences 864.55
Lupin 2175.65
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×